Reposal
Clinical data | |
---|---|
Other names | Reposamal, 5-Ethyl-5-(bicyclo(3.2.1)octenyl)barbituric acid |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C14H18N2O3 |
Molar mass | 262.309 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.[1][2][3]
References
[edit]- ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. I. Pharmacodynamic Activity". Ugeskrift for Laeger (in Danish). 125: 1735–8. PMID 14103836.
- ^ Kessing SV, Tarding F, Thomsen AC (December 1963). "Reposal, A New Hypnotic. Ii. Clinical Effects". Ugeskrift for Laeger (in Danish). 125: 1739–41. PMID 14103837.
- ^ Nielsen P, Tarding F (1968). "The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal)". Acta Pharmacologica et Toxicologica. 26 (6): 521–30. doi:10.1111/j.1600-0773.1968.tb00471.x. PMID 5756387.